# A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)

> **NCT06309992** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 218 (actual)

## Conditions studied

- Obesity
- Non-Alcoholic SteatoHepatitis (NASH)

## Interventions

- **COMBINATION_PRODUCT:** Survodutide
- **COMBINATION_PRODUCT:** Placebo

## Key facts

- **NCT ID:** NCT06309992
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-02
- **Primary completion:** 2025-10-09
- **Final completion:** 2025-12-02
- **Target enrollment:** 218 (ACTUAL)
- **Last updated:** 2026-04-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06309992

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06309992, "A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06309992. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*